BTIG Maintains a Buy on Ardelyx, Inc (ARDX)

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earlier on November 4, Allison Bratzel from Piper Sandler raised the firm’s price target on the stock from $9 to $10, while keeping a Hold rating on the stock.

​The ratings follow the company’s fiscal Q3 2025, released on October 30, where the company topped estimates. The revenue grew 12.3% year-over-year to $110.33 million, surpassing estimates by $9.78 million. The EPS of $0.00 also topped estimates by $0.07. Management attributed revenue growth to a 92% year-over-year growth in IBSRELA revenue, which reached $78.2 million, surpassing the company’s estimates by $7 million. Management noted that the outperformance of IBSRELA is driven by sustained demand for a differentiated treatment option by IBS-C patients. Therefore, the company raised IBSRELA guidance and expects 2025 revenue to be between $270 million and $275 million.

​Bratzel from Piper Sandler noted the growth in IBSERLA proves the company’s sales force strength. However, the firm awaits formal evidence of Xphozah’s near- and immediate-term outlook to formulate a more constructive opinion on Ardelyx, Inc. (NASDAQ:ARDX).

​Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that develops and commercializes first-in-class medicines for gastrointestinal and kidney-related diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.